Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Date:11/27/2007

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
(Date:7/28/2014)... MA (PRWEB) July 28, 2014 Immunomic ... two researchers to further develop potential treatments for glioblastoma ... tumor, in combination with their patented vaccine platform, LAMP-vax. ... Duke University, are based on the work of John ... Neurosurgery at The Preston Robert Tisch Brain Tumor Center ...
(Date:7/28/2014)... It’s a hard truth: Nearly half of recent ... post-secondary education are failing to obtain a diploma or certificate ... according to an analysis by The Resume Place , ... choice of college majors, which leads to underemployment, unemployment or ... 51.7 percent of post-9/11 veterans using GI Bill ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
Breaking Biology Technology:JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4
... Veracyte, Inc ., a molecular diagnostics company pioneering the ... of Mark Spring as chief financial officer. ... the Veracyte team," said Bonnie Anderson, Veracyte,s cofounder and ... and senior finance leader in both public and private ...
... Calif., Jan. 26, 2012 Cepheid (Nasdaq: CPHD ... of $80.1 million.  Net loss was $1.6 million, or $(0.03) ... net income of $1.3 million, or $0.02 per diluted share, ... quarter net loss reflected a one-time, non-cash charge to cost ...
... Lend Lease is pleased to announce the appointment of ... Sciences group in the Atlantic Region.  Tom rejoined Lend ... of the Raleigh, NC office, working closely with the regional ... Atlantic offices. He will report directly to Steve Eberling, ...
Cached Biology Technology:Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Cepheid Reports Fourth Quarter and Full Year 2011 Results 2Cepheid Reports Fourth Quarter and Full Year 2011 Results 3Cepheid Reports Fourth Quarter and Full Year 2011 Results 4Cepheid Reports Fourth Quarter and Full Year 2011 Results 5Cepheid Reports Fourth Quarter and Full Year 2011 Results 6Cepheid Reports Fourth Quarter and Full Year 2011 Results 7Cepheid Reports Fourth Quarter and Full Year 2011 Results 8Cepheid Reports Fourth Quarter and Full Year 2011 Results 9Cepheid Reports Fourth Quarter and Full Year 2011 Results 10Cepheid Reports Fourth Quarter and Full Year 2011 Results 11Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region 2
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... -- Microorganisms like bacteria and fungi can evade treatment ... or antifungal drugs. These permanent mutations were once thought ... evolve. Now a new study has shown that microorganisms ... known as epimutations -- to gain the benefits of ... mechanism was discovered in a fungus called Mucor circinelloides, ...
(Date:7/27/2014)... "big data," a single computer cannot always find the ... distributed across a cluster of computers that analyze a ... mine your web history to present you with targeted ... favorite book or movie. But big data is about ... monitoring brain activity are generating unprecedented quantities of information. ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5
... research suggests a higher-protein, lower-carbohydrate energy-restricted diet has a ... and increasing lean muscle, particularly when the proteins come ... September issue of the Journal of Nutrition, ... healthy, premenopausal women. Each consumed either low, medium ...
... wastewater recycling processes may generate more greenhouse gases than ... reasons to continue keep wastewater recycling among the water-resource ... of a new paper by Amy Townsend-Small, assistant professor ... and a team of researchers from the University of ...
... whizzes at learning a second language, but that ability begins ... at the University of Washington,s Institute for Learning & Brain ... prowess at learning languages, with the hope that the findings ... study, the researchers report that the brains of babies raised ...
Cached Biology News:Foods rich in protein, dairy products help dieters preserve muscle and lose belly fat: study 2Wastewater recycling can multiply greenhouse gas emissions 2Wastewater recycling can multiply greenhouse gas emissions 3Bilingual babies' vocabulary linked to early brain differentiation 2Bilingual babies' vocabulary linked to early brain differentiation 3
... PCRx Enhancer System is ... polymerases to optimize PCR of ... 10X PCRX Enhancer Solution with ... higher primer specificity broader magnesium ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Mouse Exodus 2 - 12kDa...
Fibulin-2 (D-15)...
Biology Products: